Compare · BIIB vs TWST
BIIB vs TWST
Side-by-side comparison of Biogen Inc. (BIIB) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $32.03B, about 3.3x TWST ($9.65B).
- Over the past year, BIIB is up 59.0% and TWST is up 431.3% - TWST leads by 372.3 points.
- TWST has been more active in the news (27 items in the past 4 weeks vs 7 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 15 for TWST).
- Company
- Biogen Inc.
- Twist Bioscience Corporation
- Price
- $216.78+1.10%
- $145.59+6.75%
- Market cap
- $32.03B
- $9.65B
- 1M return
- +8.08%
- +57.42%
- 1Y return
- +58.96%
- +431.27%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 7
- 27
- Recent ratings
- 25
- 15
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest BIIB
- Biogen upgraded by Wolfe Research with a new price target
- SEC Form 3 filed by new insider Parini Michael
- Biogen Completes Acquisition of RayThera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Director Minor Lloyd sold $239,750 worth of shares (1,186 units at $202.15), decreasing direct ownership by 31% to 2,689 units (SEC Form 4)
- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
- Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Biogen Inc.
- Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
Latest TWST
- Officer Cho Dennis sold $1,843,099 worth of shares (14,205 units at $129.75) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 75,661 units (SEC Form 4)
- President and COO Finn Patrick John exercised 23,355 shares at a strike of $67.85 and sold $9,217,607 worth of shares (78,355 units at $117.64) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 214,678 units (SEC Form 4)
- Twist Bioscience Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Twist Bioscience Corporation
- SEC Form SCHEDULE 13G filed by Twist Bioscience Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation
- Chief Executive Officer Leproust Emily M. exercised 113,318 shares at a strike of $26.66 and sold $14,183,051 worth of shares (113,318 units at $125.16) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Twist Bioscience Corporation
- Director Chess Robert sold $2,042,261 worth of shares (18,417 units at $110.89) as part of a pre-agreed trading plan and exercised 18,417 shares at a strike of $11.89 (SEC Form 4)